MAPK-pT202Y204 (gene: MAPK1, mitogen-activated protein kinase 1), a potential drug target in ccRCC, has been proven to participate in the regulation of ccRCC and other kinds of cancers (Gupta et al., 2017; Zununi Vahed et al., 2017; Gong et al., 2019). This evidence concerns the gene MAP3K1 and nonpapillary renal cell carcinoma.